BioCentury | Nov 23, 2015
Clinical News

Bilastine regulatory update

...Taiho submitted an NDA in Japan for bilastine to treat allergic rhinitis, urticaria and itching resulting...
...and cutaneous pruritus. The histamine H1 receptor (HRH1) antagonist is approved in the EU as Bilaxten...
...Farma S.A. , Madrid, Spain Taiho Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Bilastine ( TAC-202...
BioCentury | May 7, 2012
Company News

Faes, Menarini sales and marketing update

...Faes granted Menarini's Invida Holdings Pte. Ltd. exclusive rights to commercialize bilastine in Asia-Pacific markets. The...
...and Cambodia. Faes will receive an upfront payment and will be eligible for milestone payments. Bilastine...
BioCentury | Jul 19, 2010
Company News

Faes, Pierre Fabre sales and marketing update

...Pierre Fabre received non-exclusive rights to market Faes Farma's Bilastine in France and Belgium. Pierre Fabre...
...which has rights under a 2007 deal. Faes Farma submitted an MAA last year for Bilastine...
BioCentury | Jan 21, 2008
Company News

Inspire, Faes deal

...Inspire ended a 2006 deal to develop and commercialize Faes' oral bilastine in the U.S. and...
...testing to treat cystic fibrosis (CF). Faes intends to find a new commercial partner for bilastine...
BioCentury | Jun 25, 2007
Company News

Inspire, Faes deal

...2006 deal that granted ISPH exclusive U.S. and Canadian rights to commercialize and develop oral bilastine...
BioCentury | Nov 6, 2006
Strategy

A shelf full of antihistamines

...ISPH, Durham, N.C.) last week obtained U.S. and Canadian rights to develop and commercialize oral bilastine...
...market, while ISPH's licensed intranasal version competes in the $2.7 billion allergy nasal spray market. Bilastine...
...$82 million in milestones, plus a 14-16% royalty on U.S. and Canadian sales of oral bilastine...
BioCentury | Nov 6, 2006
Strategy

Bases covered

...solution Histamine H1 receptor antagonist Prevent ocular itching associated with allergic conjunctivitis Ocular Mkt Allergan Bilastine...
BioCentury | Nov 6, 2006
Company News

Inspire, Faes deal

...granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine...
...$82 million in milestones, plus a 14-16% royalty on U.S. and Canadian sales of oral bilastine...
...two European Phase III trials of the oral formulation to treat seasonal allergic rhinitis. Oral bilastine...
BioCentury | Nov 2, 2006
Company News

Inspire licenses Faes' bilastine

...granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine...
...$82 million in milestones, plus a 14-16% royalty on U.S. and Canadian sales of oral bilastine...
Items per page:
1 - 9 of 9